Avelumab Receives Fast-Track for Merkel Cell Carcinoma


The PD-L1 inhibitor was granted orphan drug status just last month.

A new PD-L1 inhibitor being developed by Pfizer and Merck has been placed on the Fast Track by the FDA. Avelumab is a fully humanized anti-PD-L1 monoclonal antibody being developed for metastatic Merkel cell carcinoma (MCC), an aggressive form of skin cancer. Just last month, the 2 companies published a joint press release announcing the orphan drug designation for avelumab.

The drug continues to be evaluated in a phase 2 study (JAVELIN Merkel 200) to assess safety and efficacy in in patients with metastatic MCC who have progressed after at least 1 prior chemotherapy regimen. The trial program for JAVELIN is simultaneoulsy testing the drug in patients with non-small cell lung cancer who have progressed on platinum-containing doublet therapy and in patients with advanced solid tumors.

Related Videos
dr mohamad mohty
dr ryan jacobs
Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"
Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Cente
A panel of experts on Alzheimer's disease
Related Content
CH LogoCenter for Biosimilars Logo